Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson's Disease

Tremor Other Hyperkinet Mov (N Y). 2020 Jul 8:10:20. doi: 10.5334/tohm.403.

Abstract

Background: The impact of slight-to-moderate levodopa-induced dyskinesia (LID) on the level of participation in active life in patients with Parkinson's disease (PD) has never been objectively determined.

Methods: Levels of LID, tremor and bradykinesia were measured during best-ON state in 121 patients diagnosed with PD and having peak-dose LID using inertial sensors positioned on each body limb. Rigidity and postural instability were assessed using clinical evaluations. Cognition and depression were assessed using the MMSE and the GDS-15. Participation in active life was assessed in patients and in 69 healthy controls using the Activity Card Sort (ACS), which measures levels of activity engagement and activities affected by the symptomatology. Outcome measures were compared between patients and controls using ANCOVA, controlling for age or Wilcoxon-Mann-Whitney tests. Spearman correlations and multivariate analyses were then performed between symptomatology and ACS scores.

Results: Patients had significantly lower activity engagement than controls and had significantly affected activities. LID was neither associated with activity engagement nor affected activities. Higher levels of tremor, postural instability, cognitive decline and depression were associated with lower activity engagement and higher affected activities. Multivariate analyses revealed that only tremor, postural instability and depression accounted significantly in the variances of these variables.

Discussion: Slight-to-moderate LID had little impact compared to other symptoms on the level of participation in active life, suggesting that other symptoms should remain the treatment priority to maintain the level of participation of patients in an active lifestyle.

Keywords: Activity engagement; Every-day life; Levodopa-induced dyskinesia; Parkinson’s disease; Participation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activities of Daily Living*
  • Aged
  • Cross-Sectional Studies
  • Dopamine Agents / adverse effects
  • Dyskinesia, Drug-Induced* / etiology
  • Dyskinesia, Drug-Induced* / physiopathology
  • Dyskinesia, Drug-Induced* / psychology
  • Female
  • Humans
  • Levodopa / adverse effects
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care
  • Parkinson Disease* / drug therapy
  • Parkinson Disease* / physiopathology
  • Parkinson Disease* / psychology
  • Social Participation*

Substances

  • Dopamine Agents
  • Levodopa

Grants and funding

We would like to thank the Quebec Parkinson Network and the volunteers for their participation in the study, as well as the Canadian Institutes of Health Research (CIHR) who provided funding for the study (Grant number: 201303MOP-298400-SDA-CFEB-56596).